Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV

Nov. 16, 2005

By Jennifer Boggs

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Nov. 15, 2005

By Jennifer Boggs

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Nov. 15, 2005

By Jennifer Boggs

Aphton Ends Sanofi Deal, Seeks New Insegia Partner

Nov. 11, 2005

By Jennifer Boggs

PTC Raises $26M Privately; Lead Drug To Start Phase II

Nov. 11, 2005

By Jennifer Boggs

Aphton Ends Sanofi Deal, Seeks New Insegia Partner

Nov. 11, 2005

By Jennifer Boggs

PTC Raises $26M Privately; Lead Drug To Start Phase II

Nov. 11, 2005

By Jennifer Boggs

Versant Closes $400M Fund, Seeks Early Stage Companies

Nov. 10, 2005

By Jennifer Boggs

Versant Closes $400M Fund, Seeks Early Stage Companies

Nov. 10, 2005

By Jennifer Boggs

With Lucentis BLA In Works, Genentech Reports AMD Data

Nov. 9, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...